
Daniel J Sargent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3680970/publications.pdf Version: 2024-02-01



DANIEL I SARCENT

#	Article	IF	CITATIONS
1	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. Contemporary Clinical Trials Communications, 2020, 17, 100492.	1.1	5
2	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. JCO Precision Oncology, 2020, 4, 116-127.	3.0	4
3	An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles. Journal of Biopharmaceutical Statistics, 2019, 29, 271-286.	0.8	10
4	Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer. Annals of Surgery, 2019, 269, 589-595.	4.2	283
5	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Journal of the National Cancer Institute, 2018, 110, 638-648.	6.3	90
6	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. European Journal of Cancer, 2018, 96, 115-124.	2.8	2
7	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 696-703.	2.5	11
8	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. New England Journal of Medicine, 2018, 378, 1177-1188.	27.0	699
9	A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. Journal of Biopharmaceutical Statistics, 2018, 28, 451-462.	0.8	4
10	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. JAMA Oncology, 2018, 4, 379.	7.1	104
11	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). Journal of Geriatric Oncology, 2018, 9, 24-31.	1.0	10
12	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂand COIN-B trials in the ARCAD database. European Journal of Cancer, 2018, 103, 205-213.	2.8	13
13	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	13.7	1,487
14	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). International Journal of Statistics in Medical Research, 2018, 7, 137-146.	1.0	0
15	A Bayesian doseâ€finding design incorporating toxicity data from multiple treatment cycles. Statistics in Medicine, 2017, 36, 67-80.	1.6	14
16	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1453-1486.	1.6	255
17	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology, 2017, 35, 552-560.	1.6	87
18	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Archives of Pathology and Laboratory Medicine, 2017, 141, 625-657.	2.5	75

#	Article	IF	CITATIONS
19	Molecular Biomarkers for the Evaluation of Colorectal Cancer. Journal of Molecular Diagnostics, 2017, 19, 187-225.	2.8	108
20	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist, 2017, 22, 189-198.	3.7	9
21	Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology. JAMA Oncology, 2017, 3, e170123.	7.1	25
22	Molecular Biomarkers for the Evaluation of Colorectal Cancer. American Journal of Clinical Pathology, 2017, 147, 221-260.	0.7	32
23	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. JAMA Oncology, 2017, 3, 472.	7.1	82
24	Prognostic Value of <i>BRAFÂ</i> andÂ <i>KRAS</i> ÂMutations in MSI and MSS Stage III Colon Cancer. Journal of the National Cancer Institute, 2017, 109, djw272.	6.3	201
25	Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. Lancet Oncology, The, 2017, 18, 143-154.	10.7	68
26	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. Oncologist, 2017, 22, 1415-1418.	3.7	7
27	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Clinical Trials, 2017, 14, 611-620.	1.6	7
28	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, 124-128.	2.3	37
29	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Journal of Oncology Practice, 2017, 13. 333-337.	2.5	29
30	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	1.6	37
31	Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). Journal of Gastrointestinal Oncology, 2017, 8, 1-11.	1.4	7
32	Title is missing!. , 2017, , .		56
33	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance) Journal of Clinical Oncology, 2017, 35, 3579-3579.	1.6	9
34	Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance) Journal of Clinical Oncology, 2017, 35, 3516-3516.	1.6	2
35	Statistics and Clinical Trials. , 2016, , 239-252.e1.		0
36	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. International Journal of Cancer, 2016, 139, 986-995.	5.1	16

#	Article	IF	CITATIONS
37	Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges. Journal of Clinical Oncology, 2016, 34, 3949-3950.	1.6	3
38	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. Journal of Geriatric Oncology, 2016, 7, 422-429.	1.0	9
39	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials. Current Colorectal Cancer Reports, 2016, 12, 251-259.	0.5	0
40	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. Ca-A Cancer Journal for Clinicians, 2016, 66, 370-374.	329.8	280
41	Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. Journal of Clinical Oncology, 2016, 34, 3711-3712.	1.6	6
42	Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. Journal of the National Cancer Institute, 2016, 108, djw154.	6.3	18
43	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist, 2016, 21, 1509-1521.	3.7	33
44	Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients. Pharmacogenetics and Genomics, 2016, 26, 133-137.	1.5	28
45	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology, The, 2016, 17, 1709-1719.	10.7	442
46	Flexible Bayesian Survival Modeling with Semiparametric Time-Dependent and Shape-Restricted Covariate Effects. Bayesian Analysis, 2016, 11, 381-402.	3.0	16
47	Testing of evaluation bias for progression free survival endpoint in oncology clinical trials. Statistics in Medicine, 2016, 35, 3923-3932.	1.6	0
48	Adjuvant Therapy for Colon Cancer. JAMA Oncology, 2016, 2, 1133.	7.1	8
49	New insights into the evaluation of randomized controlled trials for rare diseases over a longâ€ŧerm research horizon: a simulation study. Statistics in Medicine, 2016, 35, 3245-3258.	1.6	8
50	Clinical trial designs incorporating predictive biomarkers. Cancer Treatment Reviews, 2016, 43, 74-82.	7.7	61
51	One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancer. Journal of the National Cancer Institute, 2016, 108, djw011.	6.3	9
52	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. Journal of Clinical Oncology, 2016, 34, 1182-1189.	1.6	32
53	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. Journal of Clinical Oncology, 2016, 34, 843-853.	1.6	128
54	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	1.6	116

#	Article	IF	CITATIONS
55	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. Blood, 2016, 128, 1102-1102.	1.4	3
56	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. Blood, 2016, 128, 3027-3027.	1.4	5
57	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. Blood, 2016, 128, 4196-4196.	1.4	1
58	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. Chinese Clinical Oncology, 2016, 5, 80-80.	1.2	6
59	The Direct Assignment Option as a Modular Design Component: An Example for the Setting of Two Predefined Subgroups. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-6.	1.3	2
60	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. Journal of the National Cancer Institute, 2015, 107, djv239.	6.3	18
61	Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials. Journal of Clinical Oncology, 2015, 33, 36-41.	1.6	15
62	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 1036-1043.	7.0	31
63	Racial Differences in <i>BRAF</i> / <i>KRAS</i> Mutation Rates and Survival in Stage III Colon Cancer Patients. Journal of the National Cancer Institute, 2015, 107, djv186.	6.3	98
64	Improved Outcomes in Metastatic Colon Cancer. JAMA Oncology, 2015, 1, 795.	7.1	4
65	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncology, The, 2015, 16, 937-948.	10.7	286
66	Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. Clinical Colorectal Cancer, 2015, 14, 99-105.	2.3	3
67	Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points. Journal of Biopharmaceutical Statistics, 2015, 25, 857-877.	0.8	9
68	Genotype-based clinical trials in cardiovascular disease. Nature Reviews Cardiology, 2015, 12, 475-487.	13.7	37
69	Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. Journal of Clinical Oncology, 2015, 33, 4048-4057.	1.6	6
70	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clinical Cancer Research, 2015, 21, 5294-5304.	7.0	70
71	Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes. JAMA - Journal of the American Medical Association, 2015, 314, 1346.	7.4	898
72	The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. Journal of the National Cancer Institute, 2015, 107, djv157.	6.3	28

#	Article	IF	CITATIONS
73	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer, 2015, 90, 281-287.	2.0	6
74	New Adjuvant Trial Designs in Colon Cancer. Current Colorectal Cancer Reports, 2015, 11, 326-334.	0.5	2
75	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. Gastroenterology, 2015, 148, 88-99.	1.3	273
76	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	1.6	87
77	Comparing and Validating Simple Measures of Patient- Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiology & Pain Management, 2015, 2, .	0.1	9
78	Introduction to special issue on biomarker-based clinical trial designs in oncology. Chinese Clinical Oncology, 2015, 4, 28.	1.2	0
79	Randomized Phase II Clinical Trials. Journal of Biopharmaceutical Statistics, 2014, 24, 802-816.	0.8	11
80	Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the <i>KRAS</i> Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial). Clinical Cancer Research, 2014, 20, 3319-3327.	7.0	40
81	DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG) Tj ETQq1 1	0.784314 6.3	rgBT /Overloc 136
82	Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. Journal of Clinical Oncology, 2014, 32, 2975-2982.	1.6	118
83	Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research, 2014, 20, 4210-4217.	7.0	56
84	Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study. Clinical Cancer Research, 2014, 20, 4361-4369.	7.0	18
85	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	62
86	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community. European Journal of Cancer, 2014, 50, 260-266.	2.8	34
87	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. Clinical Colorectal Cancer, 2014, 13, 100-109.	2.3	41
88	<i>KRAS</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <i>BRAF</i> –Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). Clinical Cancer Research, 2014, 20, 3033-3043.	7.0	129
89	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. Journal of Clinical Oncology, 2014, 32, 1031-1039.	1.6	216
90	Shifting paradigms in cancer clinical trial design. Nature Reviews Clinical Oncology, 2014, 11, 625-626.	27.6	8

#	Article	IF	CITATIONS
91	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute, 2014, 106, .	6.3	140
92	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. Journal of Clinical Oncology, 2014, 32, 1277-1280.	1.6	354
93	Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse. Journal of Clinical Oncology, 2014, 32, 841-850.	1.6	40
94	Center-within-trial versus trial-level evaluation of surrogate endpoints. Computational Statistics and Data Analysis, 2014, 78, 1-20.	1.2	10
95	Calibration of Quality-Adjusted Life Years forÂOncology Clinical Trials. Journal of Pain and Symptom Management, 2014, 47, 1091-1099.e3.	1.2	6
96	Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. Contemporary Clinical Trials, 2014, 38, 157-162.	1.8	2
97	Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration. Forum of Clinical Oncology, 2014, 5, 1-7.	0.2	2
98	Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. The Journal of Oncopathology, 2014, 2, 37-45.	0.1	0
99	Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer. PLoS ONE, 2014, 9, e94727.	2.5	4
100	Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. Chinese Clinical Oncology, 2014, 3, 14.	1.2	9
101	Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chinese Clinical Oncology, 2014, 3, .	1.2	5
102	Drug rechallenge and treatment beyond progression—implications for drug resistance. Nature Reviews Clinical Oncology, 2013, 10, 571-587.	27.6	219
103	Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. Clinical Trials, 2013, 10, 647-652.	1.6	26
104	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	13.7	2,276
105	Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. Journal of Clinical Oncology, 2013, 31, 3664-3672.	1.6	233
106	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1667-1670.	6.3	78
107	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. European Journal of Cancer, 2013, 49, 1565-1577.	2.8	136
108	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6Âmonths) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current Colorectal Cancer Reports, 2013, 9, 261-269.	0.5	94

#	Article	IF	CITATIONS
109	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer, 2013, 119, 1528-1536.	4.1	141
110	Current Use and Surgical Efficacy of Laparoscopic Colectomy in Colon Cancer. Journal of the American College of Surgeons, 2013, 217, 56-62.	0.5	13
111	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1600-1607.	6.3	133
112	A phase II flexible screening design allowing for interim analysis and comparison with historical control. Contemporary Clinical Trials, 2013, 35, 128-137.	1.8	2
113	A review of phase II trial designs for initial marker validation. Contemporary Clinical Trials, 2013, 36, 597-604.	1.8	27
114	The Predictive and Prognostic Value of Sex inÂEarly-Stage Colon Cancer: A Pooled Analysis ofÂ33,345 Patients from the ACCENT Database. Clinical Colorectal Cancer, 2013, 12, 179-187.	2.3	27
115	Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database. Journal of Clinical Oncology, 2013, 31, 2600-2606.	1.6	211
116	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. Journal of Clinical Oncology, 2013, 31, 3656-3663.	1.6	65
117	Adaptive adjustment of the randomization ratio using historical control data. Clinical Trials, 2013, 10, 430-440.	1.6	86
118	Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147. Journal of Clinical Oncology, 2013, 31, 2016-2023.	1.6	49
119	Application of Tumor Measurement–Based Metrics in the Real World. Journal of Clinical Oncology, 2013, 31, 4374-4374.	1.6	4
120	Disease-Free Survival in Colon Cancer: Still Relevant After All These Years!. Journal of Clinical Oncology, 2013, 31, 1609-1610.	1.6	12
121	Surgical Quality Surrogates Do Not Predict Colon Cancer Survival in the Setting of Technical Credentialing. Annals of Surgery, 2013, 257, 102-107.	4.2	25
122	Mining the ACCENT database: a review and update. Chinese Clinical Oncology, 2013, 2, 18.	1.2	7
123	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1383.	7.4	412
124	Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer. Journal of the National Cancer Institute, 2012, 104, 211-227.	6.3	90
125	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. Journal of Clinical Oncology, 2012, 30, 2334-2339.	1.6	34
126	Reply to S.A. Kesikli et al. Journal of Clinical Oncology, 2012, 30, 2288-2289.	1.6	1

#	Article	IF	CITATIONS
127	From isolated hypotheses to connected practical studies: statisticians' role in a seamless targeted therapy development. Future Medicinal Chemistry, 2012, 4, 943-945.	2.3	1
128	A 2-Stage Phase II Design with Direct Assignment Option in Stage II for Initial Marker Validation. Clinical Cancer Research, 2012, 18, 4225-4233.	7.0	17
129	Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. Journal of Clinical Oncology, 2012, 30, 263-267.	1.6	483
130	Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials. Journal of Clinical Oncology, 2012, 30, 406-412.	1.6	51
131	Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups. Clinical Cancer Research, 2012, 18, 256-262.	7.0	61
132	The ARCAD Clinical Trials Program: An Update and Invitation. Oncologist, 2012, 17, 188-191.	3.7	9
133	Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. Bayesian Analysis, 2012, 7, 639-674.	3.0	132
134	CRM Trials for Assessing Toxicity and Efficacy. , 2012, , 85-96.		1
135	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncology, The, 2012, 13, e196-e204.	10.7	49
136	Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scandinavian Journal of Gastroenterology, 2012, 47, 356-362.	1.5	15
137	Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications. Clinical Cancer Research, 2012, 18, 1506-1512.	7.0	217
138	Metaâ€analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling. Biometrics, 2012, 68, 226-232.	1.4	15
139	Rejoinder for "Metaâ€analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling― Biometrics, 2012, 68, 245-247.	1.4	2
140	Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time. Biometrics, 2012, 68, 248-257.	1.4	14
141	Bayesian Adaptive Trial Design for a Newly Validated Surrogate Endpoint. Biometrics, 2012, 68, 258-267.	1.4	8
142	Prognostic Impact of FoxP3+ Regulatory T Cells in Relation to CD8+ T Lymphocyte Density in Human Colon Carcinomas. PLoS ONE, 2012, 7, e42274.	2.5	84
143	Bayesian adjusted <i>R</i> ² for the metaâ€analytic evaluation of surrogate timeâ€toâ€event endpoints in clinical trials. Statistics in Medicine, 2012, 31, 743-761.	1.6	26
144	On Bayesian methods of exploring qualitative interactions for targeted treatment. Statistics in Medicine, 2012, 31, 3693-3707.	1.6	14

#	Article	IF	CITATIONS
145	Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit. Clinical Trials, 2012, 9, 283-292.	1.6	19
146	Exploring racial differences in outcome and treatment for metastatic colorectal cancer. Cancer, 2012, 118, 1083-1090.	4.1	34
147	A phase II trial design with direct assignment option for initial marker validation Journal of Clinical Oncology, 2012, 30, 34-34.	1.6	1
148	Statistics and Clinical Trials. , 2012, , 223-237.		0
149	A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147 Journal of Clinical Oncology, 2012, 30, 446-446.	1.6	Ο
150	Use of FoxP3+ and cytotoxic CD8+ T lymphocytes to identify a patient subgroup with a favorable prognosis similar to colon cancers with deficient DNA mismatch (dMMR) repair Journal of Clinical Oncology, 2012, 30, 460-460.	1.6	0
151	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis Journal of Clinical Oncology, 2012, 30, 443-443.	1.6	Ο
152	Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials. Journal of Clinical Oncology, 2011, 29, 2781-2786.	1.6	61
153	Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics, 2011, 11, 171-182.	3.1	124
154	Failure of bevacizumab in early-stage colon cancer. Nature Reviews Clinical Oncology, 2011, 8, 10-11.	27.6	4
155	DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. Journal of the National Cancer Institute, 2011, 103, 863-875.	6.3	469
156	Optimism bias leads to inconclusive results—an empirical study. Journal of Clinical Epidemiology, 2011, 64, 583-593.	5.0	45
157	All-Comers versus Enrichment Design Strategy in Phase II Trials. Journal of Thoracic Oncology, 2011, 6, 658-660.	1.1	21
158	Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials. Biometrics, 2011, 67, 1047-1056.	1.4	250
159	Statistical Considerations for the Next Generation of Clinical Trials. Seminars in Oncology, 2011, 38, 598-604.	2.2	10
160	Long-Term Follow-Up and Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-Assisted Colectomy in the COST Trial 93-46-53 (INT 0146). Annals of Surgical Oncology, 2011, 18, 2422-2431.	1.5	68
161	Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. Annals of Surgical Oncology, 2011, 18, 3261-3270.	1.5	30
162	Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments. Current Oncology Reports, 2011, 13, 42-49.	4.0	21

#	Article	IF	CITATIONS
163	Prognostic webâ€based models for stage II and III colon cancer. Cancer, 2011, 117, 4155-4165.	4.1	25
164	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. Computational Statistics and Data Analysis, 2011, 55, 2748-2757.	1.2	23
165	Design of clinical trials for biomarker research in oncology. Clinical Investigation, 2011, 1, 1627-1636.	0.0	21
166	Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy—An Aide et Recherche en Cancérologie Digestive Group Study. Journal of Clinical Oncology, 2011, 29, 4199-4204.	1.6	51
167	Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials. Clinical Cancer Research, 2011, 17, 6592-6599.	7.0	27
168	Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741. Oncologist, 2011, 16, 859-867.	3.7	16
169	Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. Journal of the National Cancer Institute, 2011, 103, 1498-1506.	6.3	61
170	Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1199.	7.4	10
171	Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue. Journal of Clinical Oncology, 2011, 29, 4620-4626.	1.6	178
172	Systemic Therapy for Elderly Patients with Gastrointestinal Cancer. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S6983.	1.3	2
173	Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival. Clinical Trials, 2011, 8, 581-590.	1.6	7
174	Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies. Journal of Clinical Oncology, 2011, 29, 4719-4720.	1.6	33
175	Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741. Journal of Clinical Oncology, 2011, 29, 1599-1606.	1.6	85
176	Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clinical Trials, 2011, 8, 591-600.	1.6	20
177	Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. Biostatistics, 2011, 12, 478-492.	1.5	31
178	Phase III Clinical Trials with Anticancer Agents. , 2011, , 163-188.		0
179	Randomized Phase II Trials: Time for a New Era in Clinical Trial Design. Journal of Thoracic Oncology, 2010, 5, 932-934.	1.1	53
180	Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. International Journal of Oncology, 2010, 36, 601-6.	3.3	43

#	Article	IF	CITATIONS
181	Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future. Annals of Surgical Oncology, 2010, 17, 947-949.	1.5	5
182	Predictive biomarker validation in practice: lessons from real trials. Clinical Trials, 2010, 7, 567-573.	1.6	83
183	Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology, 2010, 28, 3227-3233.	1.6	198
184	Modelâ€based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer, 2010, 116, 1691-1698.	4.1	20
185	Modelâ€based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges. Statistics in Medicine, 2010, 29, 1077-1083.	1.6	55
186	Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials. Journal of Clinical Oncology, 2010, 28, 1936-1941.	1.6	96
187	Clinical Trials Data Collection: When Less Is More. Journal of Clinical Oncology, 2010, 28, 5019-5021.	1.6	11
188	Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clinical Trials, 2010, 7, 312-321.	1.6	87
189	Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors. Clinical Cancer Research, 2010, 16, 1884-1893.	7.0	191
190	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. JAMA - Journal of the American Medical Association, 2010, 303, 1729.	7.4	711
191	Reply to D.J. Stewart. Journal of Clinical Oncology, 2010, 28, e652-e653.	1.6	3
192	Reply to M.A. Rosen et al. Journal of Clinical Oncology, 2010, 28, e161-e161.	1.6	1
193	Toward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials Program. Journal of Clinical Oncology, 2010, 28, 527-530.	1.6	23
194	Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. Journal of Clinical Pathology, 2010, 63, 530-537.	2.0	31
195	Reply to C.D. Atkins. Journal of Clinical Oncology, 2010, 28, e747-e747.	1.6	0
196	Reply to P. Prassopoulos et al. Journal of Clinical Oncology, 2010, 28, e82-e82.	1.6	0
197	Blinded Independent Central Review of the Progression-Free Survival Endpoint. Oncologist, 2010, 15, 492-495.	3.7	37
198	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. Journal of Clinical Oncology, 2010, 28, 460-465.	1.6	67

#	Article	IF	CITATIONS
199	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. Journal of Clinical Oncology, 2010, 28, 3219-3226.	1.6	1,352
200	Revised Tumor and Node Categorization for Rectal Cancer Based on Surveillance, Epidemiology, and End Results and Rectal Pooled Analysis Outcomes. Journal of Clinical Oncology, 2010, 28, 256-263.	1.6	204
201	Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation. Journal of Clinical Oncology, 2010, 28, 3002-3007.	1.6	42
202	Reply to I.D. Nagtegaal et al. Journal of Clinical Oncology, 2010, 28, e399-e400.	1.6	0
203	The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research, 2010, 16, 1764-1769.	7.0	143
204	Causal Effects of Treatments for Informative Missing Data due to Progression/Death. Journal of the American Statistical Association, 2010, 105, 912-929.	3.1	9
205	Designing a Randomized Clinical Trial to Evaluate Personalized Medicine: A New Approach Based on Risk Prediction. Journal of the National Cancer Institute, 2010, 102, 1756-1759.	6.3	14
206	What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?. Oncologist, 2010, 15, 19-23.	3.7	31
207	Biomarkers and surrogate end points—the challenge of statistical validation. Nature Reviews Clinical Oncology, 2010, 7, 309-317.	27.6	283
208	Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data. Journal of Clinical Oncology, 2010, 28, 264-271.	1.6	481
209	Randomized Phase II Trials: Inevitable or Inadvisable?. Journal of Clinical Oncology, 2010, 28, 2641-2647.	1.6	78
210	Clinical Validation of Biomarkers in Cancer. , 2010, , 227-250.		0
211	Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Transactions of the American Clinical and Climatological Association, 2010, 121, 21-32; discussion 32-3.	0.5	2
212	CAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATH. Journal of the American Statistical Association, 2010, 105, 912-929.	3.1	6
213	Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2492-2500.	2.5	37
214	Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 1948-1955.	1.6	160
215	Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. Journal of Clinical Oncology, 2009, 27, 3677-3683.	1.6	1,166
216	Early Stopping for Benefit in National Cancer Institute–Sponsored Randomized Phase III Trials: The System Is Working. Journal of Clinical Oncology, 2009, 27, 1543-1544.	1.6	8

#	Article	IF	CITATIONS
217	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. Journal of Clinical Oncology, 2009, 27, 872-877.	1.6	539
218	Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841. Journal of Clinical Oncology, 2009, 27, 2848-2854.	1.6	59
219	Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials. Journal of Clinical Oncology, 2009, 27, 5958-5964.	1.6	36
220	Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147. Oncology, 2009, 77, 120-123.	1.9	67
221	Current Issues in Oncology Drug Development, with a Focus on Phase II Trials. Journal of Biopharmaceutical Statistics, 2009, 19, 556-562.	0.8	19
222	Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All. Journal of Biopharmaceutical Statistics, 2009, 19, 530-542.	0.8	106
223	Evaluation of the Optimal Number of Lesions Needed for Tumor Evaluation Using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group Investigation. Journal of Clinical Oncology, 2009, 27, 3205-3210.	1.6	34
224	NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial. Oncologist, 2009, 14, 970-978.	3.7	11
225	Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial. Journal of Clinical Oncology, 2009, 27, 4109-4115.	1.6	74
226	Postoperative Surveillance Recommendations for Early Stage Colon Cancer Based on Results From the Clinical Outcomes of Surgical Therapy Trial. Journal of Clinical Oncology, 2009, 27, 3671-3676.	1.6	91
227	Reply to F. Montagnani et al. Journal of Clinical Oncology, 2009, 27, e134-e135.	1.6	0
228	Alternate Endpoints for Screening Phase II Studies. Clinical Cancer Research, 2009, 15, 1873-1882.	7.0	78
229	Cost implications of new treatments for advanced colorectal cancer. Cancer, 2009, 115, 2081-2091.	4.1	54
230	Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. International Journal of Clinical Oncology, 2009, 14, 102-111.	2.2	70
231	Evolving end points for clinical trials in advanced colorectal cancer. Current Colorectal Cancer Reports, 2009, 5, 135-139.	0.5	1
232	Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer. Biometrics, 2009, 65, 1030-1040.	1.4	14
233	Optimising the design of phase II oncology trials: The importance of randomisation. European Journal of Cancer, 2009, 45, 275-280.	2.8	119
234	Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma. Gastroenterology, 2009, 137, 1270-1279.	1.3	273

#	Article	IF	CITATIONS
235	Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144. Clinical Colorectal Cancer, 2009, 8, 88-93.	2.3	64
236	Genomic advances and their impact on clinical trial design. Genome Medicine, 2009, 1, 69.	8.2	16
237	Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges. Journal of Clinical Oncology, 2009, 27, 4027-4034.	1.6	364
238	Clinical implications of microsatellite instability in sporadic colon cancers. Current Opinion in Oncology, 2009, 21, 369-373.	2.4	80
239	Reply to M. Chao et al. Journal of Clinical Oncology, 2009, 27, e281-e281.	1.6	1
240	Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clinical Colorectal Cancer, 2009, 8, 88-93.	2.3	2
241	Importance of randomization in early clinical trials. Clinical Advances in Hematology and Oncology, 2009, 7, 249-51.	0.3	Ο
242	Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group. Current Colorectal Cancer Reports, 2008, 4, 155-159.	0.5	1
243	A falseâ€discoveryâ€rateâ€based loss framework for selection of interactions. Statistics in Medicine, 2008, 27, 2004-2021.	1.6	3
244	Systematic review of statistical methods used in molecular marker studies in cancer. Cancer, 2008, 112, 1862-1868.	4.1	35
245	North Central Cancer Treatment Group—Achievements and Perspectives. Seminars in Oncology, 2008, 35, 530-544.	2.2	6
246	Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis. Cancer Investigation, 2008, 26, 439-444.	1.3	14
247	Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). Journal of Clinical Oncology, 2008, 26, 5326-5334.	1.6	654
248	Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer. Clinical Cancer Research, 2008, 14, 3408-3415.	7.0	218
249	Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas. Clinical Cancer Research, 2008, 14, 5810-5818.	7.0	74
250	Surrogate endpoint validation: statistical elegance versus clinical relevance. Statistical Methods in Medical Research, 2008, 17, 477-486.	1.5	26
251	Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. Journal of Clinical Oncology, 2008, 26, 183-189.	1.6	169
252	Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?. Journal of Clinical Oncology, 2008, 26, 1922-1923.	1.6	70

#	Article	IF	CITATIONS
253	Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741. Journal of Clinical Oncology, 2008, 26, 5721-5727.	1.6	274
254	New Lessons From "Old―Chemotherapy in Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 4532-4534.	1.6	5
255	Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers. Clinical Cancer Research, 2008, 14, 4128-4133.	7.0	41
256	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. Clinical Cancer Research, 2008, 14, 8263-8269.	7.0	52
257	Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set. Journal of Clinical Oncology, 2008, 26, 2336-2341.	1.6	193
258	Surgeon Volume Does Not Predict Outcomes in the Setting of Technical Credentialing. Annals of Surgery, 2008, 248, 746-750.	4.2	63
259	Genomic classifiers in colon cancer - clinical utility. Gastrointestinal Cancer Research: GCR, 2008, 2, S35-7.	0.7	1
260	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 5218-5224.	1.6	321
261	Adjuvant Therapy in the Elderly: Making the Right Decision. Journal of Clinical Oncology, 2007, 25, 1870-1875.	1.6	75
262	Smoothing Balanced Single-Error-Term Analysis of Variance. Technometrics, 2007, 49, 12-25.	1.9	25
263	Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. Journal of Clinical Oncology, 2007, 25, 2313-2321.	1.6	25
264	Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741. Journal of Clinical Oncology, 2007, 25, 3469-3474.	1.6	68
265	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. Journal of Clinical Oncology, 2007, 25, 4569-4574.	1.6	220
266	End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal. Journal of Clinical Oncology, 2007, 25, 3572-3575.	1.6	66
267	Sound Footing or Slippery Slope? The Value of Secondary Analyses of Randomized Trials. Journal of Clinical Oncology, 2007, 25, 3191-3193.	1.6	2
268	Laparoscopically Assisted vs Open Colectomy for Colon Cancer. Archives of Surgery, 2007, 142, 298.	2.2	485
269	Laparoscopic Colectomy for Cancer Is Not Inferior to Open Surgery Based on 5-Year Data From the COST Study Group Trial. Annals of Surgery, 2007, 246, 655-664.	4.2	962
270	Adverse-event rates: journals versus databases. Lancet, The, 2007, 369, 171-172.	13.7	3

#	Article	IF	CITATIONS
271	Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. Lancet, The, 2007, 370, 105-107.	13.7	33
272	CAIRO and FOCUS – Authors' reply. Lancet, The, 2007, 370, 1905.	13.7	2
273	FDC-PET Lymphoma Demonstration Project Invitational Workshop. Academic Radiology, 2007, 14, 330-339.	2.5	27
274	Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. International Journal of Cancer, 2007, 120, 1232-1238.	5.1	32
275	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX). Cancer, 2007, 110, 670-677.	4.1	29
276	Prediction of Radial Distance of Extraprostatic Extension FromÂPretherapy Factors. International Journal of Radiation Oncology Biology Physics, 2007, 69, 411-418.	0.8	18
277	Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials, 2007, 8, 14.	1.6	81
278	An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Statistics in Medicine, 2007, 26, 2317-2330.	1.6	72
279	Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial. Journal of Clinical Oncology, 2006, 24, 3347-3353.	1.6	205
280	Prognostic Impact of Microsatellite Instability and DNA Ploidy in Human Colon Carcinoma Patients. Gastroenterology, 2006, 131, 729-737.	1.3	195
281	Randomized Clinical Trial of High-Dose Levamisole Combined with 5-Fluorouracil and Leucovorin as Surgical Adjuvant Therapy for High-Risk Colon Cancer. Clinical Colorectal Cancer, 2006, 6, 133-139.	2.3	28
282	Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Annals of Surgical Oncology, 2006, 13, 887-898.	1.5	89
283	Microsatellite Instability Accounts for Tumor Site-Related Differences in Clinicopathologic Variables and Prognosis in Human Colon Cancers. American Journal of Gastroenterology, 2006, 101, 2818-2825.	0.4	70
284	Pick the Winner Designs in Phase II Cancer Clinical Trials. Journal of Thoracic Oncology, 2006, 1, 5-6.	1.1	8
285	Pick the Winner Designs in Phase II Cancer Clinical Trials. Journal of Thoracic Oncology, 2006, 1, 5-6.	1.1	4
286	An adaptive dose-finding design incorporating both toxicity and efficacy. Statistics in Medicine, 2006, 25, 2365-2383.	1.6	159
287	Is En-Bloc Resection of Locally Recurrent Rectal Carcinoma Involving the Urinary Tract Indicated?. Annals of Surgical Oncology, 2006, 13, 740-744.	1.5	14
288	Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability. Clinical Cancer Research, 2006, 12, 2738-2744.	7.0	42

#	Article	IF	CITATIONS
289	Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer. Journal of Clinical Oncology, 2006, 24, 4085-4091.	1.6	443
290	End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Diseaseâ€Free Survival as a Surrogate End Point for Overall Survival?. Oncologist, 2006, 11, 624-629.	3.7	66
291	Sam Wieand, PhD. Journal of Clinical Oncology, 2006, 24, 4523-4525.	1.6	9
292	Duffy-Santner Confidence Intervals for the Two-Stage Three-Outcome Design. Journal of Biopharmaceutical Statistics, 2006, 16, 875-880.	0.8	1
293	General and statistical hierarchy of appropriate biologic endpoints. Oncology, 2006, 20, 5-9.	0.5	62
294	Pick the winner designs in phase II cancer clinical trials. Journal of Thoracic Oncology, 2006, 1, 5-6.	1.1	3
295	A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery, 2005, 138, 618-630.	1.9	462
296	A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract. Cancer, 2005, 103, 559-568.	4.1	31
297	Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer, 2005, 104, 1871-1884.	4.1	33
298	Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation. Clinical Cancer Research, 2005, 11, 6466-6471.	7.0	54
299	Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1402-1410.	2.5	18
300	Adjuvant Therapy for Colon Cancer — The Pace Quickens. New England Journal of Medicine, 2005, 352, 2746-2748.	27.0	22
301	Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study. Journal of Clinical Oncology, 2005, 23, 9243-9249.	1.6	475
302	Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First Line. Journal of Clinical Oncology, 2005, 23, 9441-9442.	1.6	226
303	Dealing With a Deluge of Data: An Assessment of Adverse Event Data on North Central Cancer Treatment Group Trials. Journal of Clinical Oncology, 2005, 23, 9275-9281.	1.6	37
304	FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer. Journal of Clinical Oncology, 2005, 23, 3311-3313.	1.6	23
305	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. Journal of Clinical Oncology, 2005, 23, 8664-8670.	1.6	607
306	Clinical Trial Designs for Prospective Validation of Biomarkers. Molecular Diagnosis and Therapy, 2005, 5, 317-325.	3.3	44

#	Article	IF	CITATIONS
307	Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials. Journal of Clinical Oncology, 2005, 23, 2020-2027.	1.6	473
308	5-Fluorouracil–Based Chemotherapy for Advanced Colorectal Cancer in Elderly Patients: A North Central Cancer Treatment Group Study. Clinical Colorectal Cancer, 2005, 4, 325-331.	2.3	39
309	A Comparison of Laparoscopically Assisted and Open Colectomy for Colon Cancer. New England Journal of Medicine, 2004, 350, 2050-2059.	27.0	3,258
310	New Treatment Options for Colorectal Cancer. New England Journal of Medicine, 2004, 351, 391-392.	27.0	35
311	Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. Journal of Clinical Oncology, 2004, 22, 1797-1806.	1.6	913
312	Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130. Journal of Clinical Oncology, 2004, 22, 3277-3283.	1.6	109
313	Substitution of Oral Fluoropyrimidines for Infusional Fluorouracil With Radiotherapy: How Much Data Do We Need?. Journal of Clinical Oncology, 2004, 22, 2978-2981.	1.6	27
314	Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer. Journal of Clinical Oncology, 2004, 22, 1572-1582.	1.6	119
315	Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. Journal of Clinical Oncology, 2004, 22, 1209-1214.	1.6	1,007
316	Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer. Journal of Clinical Oncology, 2004, 22, 1785-1796.	1.6	419
317	Mortality associated with daily bolus 5â€fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer, 2004, 101, 2170-2176.	4.1	66
318	A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 23-30.	1.6	2,112
319	Intraoperative radiotherapy for head and neck and skull base cancer. Head and Neck, 2003, 25, 217-226.	2.0	28
320	A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1305-1310.	0.8	30
321	Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. New England Journal of Medicine, 2003, 349, 247-257.	27.0	1,962
322	Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls. Journal of Clinical Oncology, 2003, 21, 395-396.	1.6	13
323	Title is missing!. Annals of Surgery, 2003, 237, 502-508.	4.2	36
324	Efficacy and Quality-of-Life Data Are Related in a Phase II Trial of Oral Chemotherapy in Previously Untreated Patients With Metastatic Colorectal Carcinoma. Journal of Clinical Oncology, 2002, 20, 4574-4580.	1.6	40

#	Article	IF	CITATIONS
325	Early Detection of Toxicity and Adjustment of Ongoing Clinical Trials: The History and Performance of the North Central Cancer Treatment Group's Real-Time Toxicity Monitoring Program. Journal of Clinical Oncology, 2002, 20, 4591-4596.	1.6	37
326	Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors. Journal of Clinical Oncology, 2002, 20, 1043-1048.	1.6	511
327	Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer. Journal of Clinical Oncology, 2002, 20, 1735-1743.	1.6	158
328	Short-term Quality-of-Life Outcomes Following Laparoscopic-Assisted Colectomy vs Open Colectomy for Colon Cancer <subtitle>A Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2002, 287, 321.	7.4	675
329	Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer. Journal of Clinical Oncology, 2002, 20, 1491-1498.	1.6	192
330	Issues in clinical trial design for tumor marker studies. Seminars in Oncology, 2002, 29, 222-230.	2.2	58
331	Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. International Journal of Radiation Oncology Biology Physics, 2002, 52, 469-475.	0.8	171
332	Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. International Journal of Radiation Oncology Biology Physics, 2002, 54, 409-413.	0.8	25
333	Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. International Journal of Radiation Oncology Biology Physics, 2002, 54, 386-396.	0.8	148
334	A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. Quality of Life Research, 2002, 11, 37-45.	3.1	9
335	Guidelines 2000 for Colon and Rectal Cancer Surgery. Journal of the National Cancer Institute, 2001, 93, 583-596.	6.3	1,174
336	Impact of Surgical and Pathologic Variables in Rectal Cancer: A United States Community and Cooperative Group Report. Journal of Clinical Oncology, 2001, 19, 3895-3902.	1.6	199
337	A flexible design for multiple armed screening trials. Statistics in Medicine, 2001, 20, 1051-1060.	1.6	81
338	Comparison of artificial neural networks with other statistical approaches. Cancer, 2001, 91, 1636-1642.	4.1	256
339	A Three-Outcome Design for Phase II Clinical Trials. Contemporary Clinical Trials, 2001, 22, 117-125.	1.9	74
340	Counting degrees of freedom in hierarchical and other richly-parameterised models. Biometrika, 2001, 88, 367-379.	2.4	110
341	A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients. New England Journal of Medicine, 2001, 345, 1091-1097.	27.0	931
342	Refining Multimodal Therapy for Rectal Cancer. New England Journal of Medicine, 2001, 345, 690-692.	27.0	68

#	Article	IF	CITATIONS
343	Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma. Journal of Immunotherapy, 2000, 23, 430-437.	2.4	36
344	A north central cancer treatment group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer, 2000, 89, 1699-1705.	4.1	15
345	PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER. Journal of Urology, 2000, 164, 1538-1542.	0.4	64
346	Prognostic Factors in Colorectal Cancer. Archives of Pathology and Laboratory Medicine, 2000, 124, 979-994.	2.5	1,027
347	Statistical Issues in Tumor Marker Studies. Archives of Pathology and Laboratory Medicine, 2000, 124, 1011-1015.	2.5	37
348	Decrease in cranial nerve complications after radiosurgery for acoustic neuromas: a prospective study of dose and volume. International Journal of Radiation Oncology Biology Physics, 1999, 43, 305-311.	0.8	112
349	Sample Size and Design Considerations for Phase II Clinical Trials with Correlated Observations. Contemporary Clinical Trials, 1999, 20, 242-252.	1.9	9
350	The radial distance of extraprostatic extension of prostate carcinoma. , 1999, 85, 2630-2637.		134
351	The radial distance of extraprostatic extension of prostate carcinoma. Cancer, 1999, 85, 2630-2637.	4.1	34
352	Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. International Journal of Radiation Oncology Biology Physics, 1998, 41, 593-598.	0.8	62
353	A General Framework for Random Effects Survival Analysis in the Cox Proportional Hazards Setting. Biometrics, 1998, 54, 1486.	1.4	95
354	A flexible approach to time-varying coefficients in the Cox regression setting. Lifetime Data Analysis, 1997, 3, 13-25.	0.9	38
355	ROBUST BAYESIAN APPROACHES FOR CLINICAL TRIAL MONITORING. , 1996, 15, 1093-1106.		29

Gastrointestinal Cancers. , 0, , 81-104.